

PATENT
Customer No. 22,852
Attorney Docket No. 08201.0042-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re National Stage of International
Application No. PCT/US2004/034514 of:
KALLED, Susan et al.

Application No.: To be assigned

PCT Application Filed: 20 October 2004

§ 371 date: 20 October 2003

For: THERAPEUTIC REGIMENS FOR
BAFF ANTAGONISTS

)
)
)
) Group Art Unit: To be assigned
)
) Examiner: To be assigned
)
)
) Confirmation No.: To be assigned
)
)
)

CERTIFICATE UNDER 37 CFR § 1.10 OF
MAILING BY "EXPRESS MAIL"

I hereby certify that this correspondence is being deposited with
the United States Postal Services "Express Mail Post Office to
Addressee" service under 37 CFR § 1.10 on April 19, 2006 and
is addressed to: Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450. Express Mail Label No. EV
684955995 US.


Kathleen Camire

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of
the Examiner the documents on the attached listing. This Information Disclosure
Statement is being filed within three months of the date of entry of the national stage
in an international application.

Copies of the listed foreign and non-patent literature documents are attached.
Copies of the U.S. patent publications are not enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: 19 April 2006

By: 

Konstantin Linnik
Reg. No. 56,309
Tel: (617) 452-1626

| | | | | | |
|---|---|----|---|--------------------------|---------------------------------|
| IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | To be assigned 10/576527 |
| | | | | Filing Date | Herewith (19 April 2006) |
| | | | | First Named Inventor | Susan Kalled |
| | | | | Art Unit | To be assigned |
| | | | | Examiner Name | To be assigned |
| Sheet | 1 | of | 1 | Attorney Docket Number | 08201.0042-00000 |

| U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS | | | | | |
|---|-----------------------|--|---|---|---|
| Examiner Initials | Cite No. ¹ | Document Number | Issue or Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|---|---|--------------------------|
| Examiner Initials | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | Translation ⁶ |
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | | | | |
| | | WO 02/024909 A2 | 03/28/2002 | Biogen Inc. | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|--------------------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | Translation ⁶ |
| | | International Search Report for PCT/US2004/034514, mailed 6 April 2005 from the International Searching Authority of the European Patent Office. | |
| | | Gross et al., "TACI and BCMA Are Receptors for a TNF Homologue Implicated in B-Cell Autoimmune Disease," <i>Nature</i> , 404:995-999 (2000) | |
| | | Kayagaki et al., "BAFF/BLyS Receptor 3 Binds the B Cell Survival Factor BAFF Ligand through a Discrete Surface Loop and Promotes Processing of NF- κ B2," <i>Immunity</i> , 10:515-524 (2002) | |
| | | Pelletier et al., "Comparison of Soluble Decoy IgG Fusion Proteins of BAFF-R and BCMA as Antagonists for BAFF," <i>J. Bio. Chem.</i> , 278:33127-33133 (2003) | |
| | | Stohl, W., "A Therapeutic Role For BLyS Antagonists," <i>Lupus</i> , 13:317-332 (2004) | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.